BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 18064567)

  • 1. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
    Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure.
    Fles R; Hoogendoorn WE; Platteel I; Scheerman CE; de Leeuw-Mantel G; Mourits MJ; Hollema H; van Leeuwen FE; van Boven HH; Nederlof PM
    Genes Chromosomes Cancer; 2010 Aug; 49(8):699-710. PubMed ID: 20544844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH
    Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
    Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
    Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
    Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
    Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
    Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
    Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
    Barakat RR; Wong G; Curtin JP; Vlamis V; Hoskins WJ
    Gynecol Oncol; 1994 Nov; 55(2):164-8. PubMed ID: 7959278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
    Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
    Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
    Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.
    Ngô C; Brugier C; Plancher C; de la Rochefordière A; Alran S; Féron JG; Malhaire C; Scholl S; Sastre X; Rouzier R; Fourchotte V;
    Eur J Surg Oncol; 2014 Oct; 40(10):1237-44. PubMed ID: 25086993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
    Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
    Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of uterine malignancies that develop during and following tamoxifen therapy.
    Ferguson SE; Soslow RA; Amsterdam A; Barakat RR
    Gynecol Oncol; 2006 May; 101(2):322-6. PubMed ID: 16352333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
    Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
    Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.